Contact Us

Opening hours: Monday to Friday: 8:00am to 5:00pm, Saturday: 8:30am to 12:30pm

SIGN UP
SIGN UP

Tag: group research

Posted on

Reducing risks of osteoporosis fractures in Crohn’s disease with impact and resistance training

Cr. John Arano

Crohn's Disease and Osteoporosis

Crohn’s Disease (CD) is a type of inflammatory bowel disease which causes your digestive tract to be swollen and irritated. 

Amazingly, CD is also linked with osteoporosis. 

This is due to the inability of the small intestines to absorb nutrients, including Vitamin D. 

Thus causing Vitamin D deficiency, a vitamin that is important for the formation of bones.

This in turn may result in osteoporosis. 

The link between CD and osteoporosis is also associated with inflammation, high-dose corticosteroid use, as well as a lack of exercise and physical activity.

Studies on Impact of Exercise to Increase Bone Mineral Density (BMD)

A recent study shows that combined impact and resistance training exercises help raise bone mineral density and muscle function. 

Thus, benefiting patients with Crohn’s disease (CD).

CD patients have a high risk of developing osteoporosis and related fractures.

Researchers selected adults with stable CD and were assigned to undergo an exercise intervention or receive usual care alone for 6 months. 

Usual care plus a combined impact and resistance training program was given to the exercise group. 

Whereas patients underwent three 60-minutes sessions per week, with a gradual tapering of supervision to self-management.

Most of the patients had the quiescent disease and none of the patients smoked. 

Result of The Study

216 months median time since the CD diagnosis and according to baseline BMD measurements, 12 patients had evidence of osteopenia or osteoporosis at the lumbar spine and 20 at the left hip. 

The most common medications used for CD were immunosuppressants and biologics; none were on corticosteroids.

The bone mineral density (BMD) values were better in the exercise group vs the control group at 6 months. 

Moreover, the difference is significant at the lumbar spine, but not at femoral neck nor at the greater trochanter.

Even though there were three exercise-related adverse events (for instance light-headedness and nausea) the intervention yielded improvements in all muscle function outcomes and fatigue severity.

The findings highlight the intervention as a suitable model of exercise for reducing the future risk of osteoporotic fractures and physical disability in this high‐risk population.

For more articles alike, click HERE!

References

  1. https://specialty.mims.com/

Share the post!

Posted on

No adverse CV outcomes and excess risks of death from Febuxostat

Cr. Halacious

Source from MIMS.com

According to the results of a meta-analysis, the use of febuxostat does not appear to come with an increased hazard of mortality or adverse cardiovascular (CV) outcomes, for the treatment of patients with gout and hyperuricemia.

Data from 15 randomized controlled trials were collected by researchers and contributed to a total of 16,070 participants. The proportion of patients with hypertension varied between 27.7 percent and 100.0 percent, while those with diabetes ranged from 6.9 percent to 100.0 percent.

A median follow-up of 6.4 months were used across the trials, and the use of febuxostat vs control (allopurinol or placebo) did not result in a significant increase in the risk of CV mortality and all-cause mortality.

The same was true for adverse CV outcomes, as follows: major adverse CV events (risk difference [RD] 1.40 percent), myocardial infarction (RD, -0.06 percent), stroke (RD, 0.10 percent), or new-onset hypertension (RD, 1.58 percent).

Among patients with existing CV disease, the findings were consistent and the test (Egger’s regression test) did not detect significant publication bias.

The evidence were limited by the presence of low to moderate certainty, the researchers said. Recommendations of evaluating CV events and mortality as an outcome were stated by the researchers, as well as defining major adverse CV events, and comparing the outcomes among different doses of febuxostat over a longer follow-up duration in future trials.

Share the post!

Posted on

Therapeutic potential in COVID-19 with colchicine

Cr. Fusion Medical Animation

Source from MIMS.com

Based on a study, survival rate in patients with COVID-19 was improved with the use of colchicine, which are usually used for the treatment of gout and other inflammatory disorders as compared with standard of care (SoC).

The well-recognised anti-inflammatory effects and potential antiviral properties made it as one of the drugs that was considered for the treatment of COVID-19.  140 hospitalized patients who contracted COVID-19 had their outcomes evaluated as they were treated with SoC (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir) and in 122 patients treated with colchicine and SoC.

The SoC group, have lower serum concentrations of C-reactive prottein and ferritin, as well as neutrophil count but higher PaO2/FiO2 ratio at baseline.

Survival when being compared over 21 days of follow-up, it was more favourable in the colchicine than the SoC group. A lower risk of death was strongly associated with colchicine, on Cox proprortional hazards regression (hazard ratio, 0.151).

At entry, there were a higher serum levels of ferritin, worse Pa02/Fi02 and poor survival at older age for the risk factors. 

With no treatment discontinuation due to severe adverse events, colchicine had a good safety profile. In nine patients, dosing was reduced from 1 to 0.5 mg/day due to diarrhoea.

With the aim of preventing the patient’s autoinflammatory response, the current study provides proof-of-concept data supporting the possible use of colchicine in the treatment of the early phase of COVID-19.

To determine the efficacy and safety of colchicine, properly designed trials are needed with the best protocol in terms of dosage and timing of administartion in patients with COVID-19, said the researchers.

Share the post!

CONTACT US

Mon to Fri: 8:00am to 5:00pm
Sat: 8:30am to 12:30pm

QUICK LINKS

QUICK LINKS

© 2025 Mayflax

Facebook Linkedin Instagram